In this episode of Medsider Radio, we sat down with Sean Morris, CEO of Amplifi, developers of the groundbreaking Vein Dilation System to improve access sites for dialysis patients.

Sean started his professional journey selling medical devices for AngioDynamics. Over his ten-year tenure with the company, Sean rose through the ranks to become the Global Vice President of Marketing and later led the entire Peripheral Vascular Division. After leaving AngioD in 2009, he embarked on various entrepreneurial ventures, including the founding of Veniti, which was acquired by Boston Scientific in 2018. He also spearheaded Euphrates Vascular, an innovative startup in the field of microvascular obstructions.

In this interview,  Sean shares the story — from his first job selling medical devices for AngioDynamics to his current role as CEO of Amplifi, how his novel Vein Dilation System is poised to revolutionize dialysis patient care, and the many lessons he’s learned bringing innovative medtech products to market as a startup CEO.

Before we dive into the discussion, I wanted to mention a few things:

If you’re into learning from proven medtech and health tech leaders and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced life science leaders about the nuts and bolts of running a business and bringing products to market.

This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, if you'd much rather read, here's a link to the full interview with Sean Morris.